{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-021051","form_type":"8-K","ticker":"ARDX","cik":"0001437402","company_name":"ARDELYX, INC.","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.764772+00:00","generated_at":"2026-06-24T03:55:03.445104+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Ardelyx Q2 net loss narrows to $26.9M; IBSRELA sales start at $1.6M","bullets":["Net product sales of IBSRELA were $1.6M in Q2 2022, first commercial quarter post-launch.","Net loss $26.9M ($0.19/share) vs $45.2M ($0.45) in Q2 2021; cash & investments $81.0M.","Entered $20M financing with HealthCare Royalty based on future royalties from Kyowa Kirin.","FDA advisory committee for XPHOZAH NDA tentatively scheduled for Nov 16, 2022.","Survey data: 41% of GIs report using IBSRELA; 92% rate it as a substantial/moderate advance."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-021051","json":"https://secwatch.observer/filing/0001628280-22-021051.json","markdown":"https://secwatch.observer/filing/0001628280-22-021051.md","text":"https://secwatch.observer/filing/0001628280-22-021051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1437402/000162828022021051/0001628280-22-021051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1437402/000162828022021051/ardx-20220804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T03:55:03.445104+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}